“3 Experts Have Resigned From An FDA Committee Over Alzheimer’s Drug Approval”

3 Experts Have Resigned From An FDA Committee Over Alzheimer’s Drug Approval,” by Bill Chappell, NPR


Quote:

“Three experts have now resigned from a Food and Drug Administration advisory committee after the agency approved an Alzheimer’s drug called Aduhelm against the wishes of nearly every member on the panel. The drug — its generic name is aducanumab — was approved on Monday, setting off a variety of responses, from celebrations among some patients, caregivers and doctors to pointed questions about the drug’s benefits and costs.”

Read full article in The Hill:  https://thehill.com/opinion/finance/557675-using-medicaid-to-protect-inheritances

LTC Comment, Stephen A. Moses, President, Center for Long-Term Care Reform:

The FDA operates under the dual mandate not to approve drugs before they’re proven safe and effective. But if a drug is safe, why not let consumers decide how worthwhile it may or may not be based on feedback from users? Probably because government pays for most drugs elderly people take. So government, instead of consumers, decides what’s best or even available to its citizens … “subjects” is more accurate. You thought you were getting something for free from Part D? You paid for it in a real, if more elusive currency—freedom of choice.